Skip to main content
Fig. 1 | Journal of Medical Case Reports

Fig. 1

From: Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

Fig. 1

Chemical analyses of the THC-rich cannabis extract and patient’s clinical cognitive evaluation timeline. A The extract analyzed has a higher prevalence of THC (8.7 ± 0.5% m/m) and lower concentration (0.75 ± 0.15%) of CBD. B A lower prevalence of other phytocannabinoids was detected. C, D Scores according to the Alzheimer’s Mini-Mental State Examination (MMSE) (C) and the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) scale (D). Bars represent different THC microdosages (µg). Dose distribution was the following: 500 µg for the initial 150 days of treatment, 750 µg for the following 60 days, 1000 µg for the next 30 days, 650 µg during the next 30 days, 350 µg for the following 60 days, 300 µg THC for 30 days, and 500 µg for the last 60 days of treatment. T0 (black bar), baseline assessment before the start of experimental treatment; T1 to T22 (bars colored in shades of green), treatment with cannabinoid extract, in which shades correspond to doses of THC, from lighter (lowest dose) to darker (highest dose)

Back to article page